Palisade Bio Announces Topline Results From U.S. Phase 2 PROFILE Study Evaluating LB1148 For Post-Surgical Abdominal Adhesions
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio (NASDAQ:PALI) announced that its U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions did not achieve its primary endpoint. The company has decided to no longer pursue the adhesions indication. However, Palisade Bio remains committed to the future and is in discussions for pipeline expansion opportunities in high value indications in the GI space.
August 09, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palisade Bio's LB1148 failed to meet its primary endpoint in a Phase 2 study. The company will no longer pursue the adhesions indication but is looking for other opportunities in the GI space.
The failure of a Phase 2 study is a significant setback for any biopharmaceutical company, as it indicates that the drug may not be effective. This could negatively impact the company's stock price in the short term. However, the company's commitment to finding other opportunities in the GI space could mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100